Bioavailability Drugs Scientist 
Pharmaceutical Technology
FEBRUARY 23, 2023
Biopharmaceutics is a scientific discipline that examines the interrelationship of the physicochemical properties of the drug, the dosage form in which the drug is given, and the route of administration on the rate and extent of systemic drug absorption ( Applied Biopharmaceutics and Pharmacokinetics, Shargel, Wu-Pong and Yu, 5th Edition ).
Camargo
FEBRUARY 10, 2021
Drug development is an extremely cumbersome process, requiring the testing of an agent from in vitro studies to in vivo studies to in silico modeling. Given that it can take up to 20 years for a final product to be approved, it is unsurprising that drug attrition rates are very high. Pharmacokinetics Scientist. Uma Fogueri, PhD.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
APRIL 20, 2023
In the first phase of its training workshops, the Pharmaceutical Innovation Center plans to develop a range of excipients [inactive substances that serve as the vehicle or medium for a drug or other active substance] for controlled release dosage forms, improving their bioavailability, along with formulating orally dispersible and chewable tablets.
Camargo
DECEMBER 22, 2021
Informed by today’s competitive drug development landscape, as well as by the sponsor’s strategic goals and capabilities, a portfolio analysis involves assessing product concept and differentiation, strategic planning, factoring in unmet patient needs, and estimating timelines and expenses. Scientist, Regulatory Strategy.
Cloudbyz
MARCH 5, 2024
In the intricate dance of drug discovery and development, two protagonists emerge as the cornerstones of modern medicine: biologics and small molecules. Manufacturing Process : Small Molecules: Manufactured through chemical synthesis, small molecule drugs can be consistently reproduced with a high degree of purity and stability.
pharmaphorum
MARCH 16, 2021
The Cardiff, Wales startup is combining machine learning and phage display techniques to model antibody-antigen binding and says it can cut the time it takes to develop a drug candidate. It’s one of the few AI drug discovery companies operating in the antibody category, as most are focused on small molecules. He added. “In
Pharmaceutical Technology
JANUARY 25, 2023
They provide a higher ability to regulate protein levels and can affect the non-enzymatic function of the protein while also providing an alternative to targeting drug-resistant proteins for overcoming tumour drug resistance.
Expert insights. Personalized for you.
246 
Let's personalize your content